

## Special Issue

# Retinal Diseases: Imaging and Treatment

### Message from the Guest Editor

The studies on retinal diseases such as AMD, diabetic retinopathy, retinal vein occlusions and inherited retinal diseases have expanded seriously over the last years. Advances in the field of retinal imaging and treatment have opened new horizons and are allowing us to have a better understanding of retinal diseases and treatment methods. Retinal imaging plays a key role not only in our daily routine but also in the field of retinal research. Today, retinal imaging is an unique supporting tool to understand retinal diseases and investigate new therapeutic methods and for the development of new treatment strategies. The aim of this special issue is to clarify the pathogenesis of the main retinal diseases using retinal imaging, in order to identify new ocular and systemic biomarkers and new therapeutic strategies, as well. In this Special Issue, we welcome original articles about the study of retinal diseases. These include, but are not limited to, AMD, diabetic retinopathy, retinal vein occlusion, inherited retinal diseases, diagnosis, clinical features and preclinical research, and clinical trials of new treatments. Thank you for your contribution.

### Guest Editor

Dr. Cengiz Türksever

Faculty of Medicine, University of Basel, 4001 Basel, Switzerland

### Deadline for manuscript submissions

closed (31 July 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/133075](https://mdpi.com/si/133075)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).